References
Abou-Zeid C, Ratliff TL, Wiker H (1988) Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG. Infect Immun 56:3046–3051
Aslanzadeh J, Brown EJ, Quillin SP, et al (1989) Characterization of soluble fibronectin binding to bacillus Calmette-Guérin. J Gen Microbiol 135:2735–2741
Brosman SA (1982) Experience with bacillus Calmette-Guérin in patients with superficial bladder cancer. J Urol 128:27–30
Brosman SA (1985) The use of bacilus Calmette-Guérin in the therapy of bladder cancer in situ. J Urol 134:36–41
Grinnell F, Billingham RE, Burgess L (1981) Distribution of fibronectin during wound healing in vivo. J Invest Dermatol 76:181–189
Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136:970–974
Hanna MG, Zbar B, Rapp HJ (1972) Histopathology of tumor regression after intralesional injection of Mycobacterium bovis: II. Comparative effects of vaccinia virus, oxalone, and turpentine. J Natl Cancer Inst 48:1697–1707
Herr HW, Pinsky CM, Whitmore WF, et al (1985) Experience with intravesical bacillus Calmetter Guérin therapy of superficial bladder tumors. Urology 25:119–123
Herr HW, Pinsky CM, Whitmore WF, et al (1986) Long-term effect of intravesical bacillus Calmetter-Guérin on flat carcinoma in situe of the bladder. J Urol 135:265–267
Hudson MA (1990) Correlation of fibronectin binding capacity and antitumor efficacy of BCG substrains (abstract). AUA
Hudson MA, Catalona WJ, Ritchey JK, et al (1989) Choice of an optimal diluent for intravesical bacillus Calmette-Guérin administration. J Urol 142:1438–1441
Hudson MA, Ritchey JK, Catalona WJ, et al (1990) Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. Cancer Res 50:3843–3847
Hudson MA, Yuan JJ, Catalona WJ, et al (1990) Adverse impact of fibrin clot inhibitors on intraversical bacillus Calmette-Guérin therapy for superficial bladder tumors. J Urol 1362–1364
Kavoussi LR, Brown EJ, Ritchey JR, et al (1990) Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa. J Clin Invest 85:62–67
Kelley DR, Haaff EO, Becich M, et al (1986) Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guérin. J Urol 135:268–271
Lamm D, Stogdill V, Stogdill B, et al (1986) Complications of bacillus Calmette-Guérin immunotherapy in 1,278 patients with bladder cancer. J Urol 135:272–274
Lamm DL, Thor DE, Stogdill UD, et al (1982) Bladder cancer immunotherapy. J Urol 128:931–935
Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Galmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180–183
Mori K, Lamm DL, Crawford DE (1986) A trial of bacillus Calmette-Guérin versus Adriamycin in superficial bladder cancer: A southwest Oncology Group study. Urol Int 41:254–259
Pode D, Alon Y, Horowitz AT (1986) The mechanism of human bladder tumor implantation in an in vitro model. J Urol 136:482–486
Ratliff TL, Gillen DP, Catalona WF (1987) Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137:155–158
Ratliff TL, Palmer JO, McGarr JA, et al (1987) Intraversical bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of bacillus Calmette-Guérin. Cancer Res 47:1762–1766
Ratliff TL, McGarr JA, Abou-Zeid C, et al (1988) Attachment of Mycobacterium to F-coated surfaces. J Gen Microbiol 134:1307–1313
Zbar B, Bernstein ID, Rapp JJ (1971) Suppression of tumor growth at the site of injection with living bacillus Calmette-Guérin. J Natl Cancer Inst 46:831–839
Author information
Authors and Affiliations
Additional information
This work was supported by USPHS grants CA 37926 (T.L.R.) and CA 44426 (T.L.R.) from the National Cancer Institute through the Bladder Cancer Project
Rights and permissions
About this article
Cite this article
Ratliff, T.L., Hudson, M.A. & Catalona, W.J. Strategy for improving therapy of superficial bladder cancer. World J Urol 9, 95–98 (1991). https://doi.org/10.1007/BF00184040
Issue Date:
DOI: https://doi.org/10.1007/BF00184040